Webster Bank N. A. Trims Stock Position in Bristol Myers Squibb Company $BMY

Webster Bank N. A. lessened its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 2.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,119 shares of the biopharmaceutical company’s stock after selling 455 shares during the quarter. Webster Bank N. A.’s holdings in Bristol Myers Squibb were worth $885,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of BMY. Brighton Jones LLC raised its position in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Bank Pictet & Cie Europe AG acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth $13,094,000. Toronto Dominion Bank grew its stake in shares of Bristol Myers Squibb by 37.2% during the 4th quarter. Toronto Dominion Bank now owns 1,145,990 shares of the biopharmaceutical company’s stock worth $64,817,000 after purchasing an additional 310,906 shares during the period. Strategic Global Advisors LLC grew its stake in shares of Bristol Myers Squibb by 4.3% during the 4th quarter. Strategic Global Advisors LLC now owns 100,816 shares of the biopharmaceutical company’s stock worth $5,702,000 after purchasing an additional 4,156 shares during the period. Finally, Stonebrook Private Inc. grew its stake in Bristol Myers Squibb by 1.9% in the 4th quarter. Stonebrook Private Inc. now owns 15,146 shares of the biopharmaceutical company’s stock valued at $857,000 after acquiring an additional 276 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Down 2.8%

Shares of BMY stock opened at $46.22 on Monday. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33. The firm’s 50-day simple moving average is $47.08 and its 200-day simple moving average is $50.07. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The firm has a market cap of $94.08 billion, a P/E ratio of 18.64, a PEG ratio of 2.36 and a beta of 0.35.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same quarter last year, the firm posted $2.07 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were given a $0.62 dividend. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.4%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 100.00%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.09% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on BMY. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a research note on Tuesday, August 5th. Daiwa America cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Citigroup reduced their target price on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday, August 1st. Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Finally, Wall Street Zen lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $56.38.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.